You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

Gastroenterology

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

MD, PhD

Seema Aceves

2 minutes

Learning objectives

Recognize the central role of type 2 inflammation and its interconnectivity with barrier dysfunction in EoE pathophysiology

Description

Join Seema Aceves, MD, PhD, as she reviews how key type 2 cytokines play a critical role in barrier dysfunction and the pathophysiology of EoE and ultimately impact patient burden.

About this expert

Allergy/Immunology

Gastroenterology

Seema Aceves

MD, PhD

Professor of Pediatrics and Medicine in the Division of Allergy and Immunology | University of California, San Diego; Director of the Eosinophilic Gastrointestinal Disorders Clinic | Rady Children’s Hospital–San Diego, California, United States

See author’s profile

Related resources

Eosinophilic Esophagitis (EoE) Interactive Patient Case

Gastroenterology

10 min

interactivity

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

Gastroenterology

12 min

audio

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

Gastroenterology

5 min

Infographic

Adaptive Behaviors in EoE Infographic

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

Learning objectives

Description

About this expert

Seema Aceves

Related resources

Eosinophilic Esophagitis (EoE) Interactive Patient Case

EoE: A Chronic, Progressive, Type 2 Inflammatory Disease

Importance of Assessing Key Disease Domains in EoE Infographic

Pediatric EoE Disease Burden Infographic

Complex EoE Pathophysiology Beyond Esophageal Eosinophilia

Esophageal Dilation Does Not Impact Underlying Inflammation in EoE

Food Bolus Impaction: An Opportunity to Diagnose EoE

Gap in Care Leads to Progression of Fibrosis in EoE

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

Importance of Assessing Multiple Disease Domains in EoE

The Need for Maintenance Therapy in EoE

Assessing EoE: Assessing Symptoms in Patients With EoE

Assessing EoE: Assessing Histologic Features in EoE

EoE Burden and Pathophysiology of Type 2 Inflammation